Stem Cell Therapies in Movement Disorders: Lessons from Clinical Trials

Stem cell-based therapies (SCT) to treat neurodegenerative disorders have promise but clinical trials have only recently begun, and results are not expected for several years. While most SCTs largely lead to a symptomatic therapeutic effect by replacing lost cell types, there may also be disease-mod...

Full description

Saved in:
Bibliographic Details
Published in:Biomedicines 2023-02, Vol.11 (2), p.505
Main Authors: Marsili, Luca, Sharma, Jennifer, Outeiro, Tiago Fleming, Colosimo, Carlo
Format: Article
Language:English
Subjects:
Amyotrophic lateral sclerosis
Ataxia
Basal ganglia
Care and treatment
Case reports
Cell therapy
Central nervous system diseases
Clinical trials
Dementia
disease-modifying therapies
Dopamine
Huntingtons disease
Movement disorders
neurodegeneration
Neurodegenerative diseases
Neurons
Parkinson's disease
Patients
Precision medicine
Review
stem cell therapies
Stem cell transplantation
Stem cells
Transplantation
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Stem cell-based therapies (SCT) to treat neurodegenerative disorders have promise but clinical trials have only recently begun, and results are not expected for several years. While most SCTs largely lead to a symptomatic therapeutic effect by replacing lost cell types, there may also be disease-modifying therapeutic effects. In fact, SCT may complement a multi-drug, subtype-specific therapeutic approach, consistent with the idea of precision medicine, which matches molecular therapies to biological subtypes of disease. In this narrative review, we examine published and ongoing trials in SCT in Parkinson's Disease, atypical parkinsonian disorders, Huntington's disease, amyotrophic lateral sclerosis, and spinocerebellar ataxia in humans. We discuss the benefits and pitfalls of using this treatment approach within the spectrum of disease-modification efforts in neurodegenerative diseases. SCT may hold greater promise in the treatment of neurodegenerative disorders, but much research is required to determine the feasibility, safety, and efficacy of these complementary aims of therapeutic efforts.
ISSN:2227-9059
2227-9059
DOI:10.3390/biomedicines11020505